Purple Biotech Ltd (PPBT) Share Price

6.27 halted up

https://x.com/THIS_TIME_X/status/1863603210973298718

https://x.com/THIS_TIME_X/status/1863568226573066260

Looking good $5s + 50% for this low floater pancreatic cancer phase 2

PPBT https://x.com/OzmosiHealth/status/1863554233485898198

https://dilutiontracker.com/app/search/PPBT?a=dbb88c

https://finviz.com/quote.ashx?t=PPBT&p=d

$3.10 down -1% low floater will gain some traction some warrants to watch 

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of DeathNovember 04 2024 - 7:50AM


Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has identified serum CEACAM1 as an additional new potential blood biomarker that may help determine which metastatic pancreatic ductal adenocarcinoma (PDAC) patients are most likely to benefit from treatment with CM24. CM24 is a humanized monoclonal antibody that blocks CEACAM1 binding thereby inhibits its activity.  CEACAM1 is overexpressed on certain tumor cells, immune cells, and neutrophils extracellular traps (NETs).PDAC patients who had pretreatment serum CEACAM1 levels between 6K and 15K pg/mL  demonstrated the best outcomes following treatment with CM24 and nivolumab in combination with irinotecan/fluoropyrimidine based chemotherapy compared to chemotherapy control, with respect to both progression free survival (PFS) (median = 4.6 months, hazard ratio [HR] < 0.1, P = 0.003) and overall survival (OS) with an 79% reduction in risk of death (HR = 0.21, P = 0.04). The median OS improved from 3.6 months with chemotherapy alone to 8.7 months with the combination.Purple Biotech’s randomized Phase 2 study of CM24 in the second line treatment of PDAC has previously identified multiple potential biomarkers including another serum-based marker, myeloperoxidase (MPO), and tumor markers.“As we look ahead to topline Phase 2 results before the end of the year and anticipate advancing CM24 into further clinical development, the identification of an additional serum biomarker for patient selection is a critical advantage for our future CM24 study and more importantly, potentially for cancer patients in need of better outcomes, particularly for pancreatic cancer,” said Gil Efron, Purple Biotech CEO.

Usually in a R/S if a person has Less than 1 share, they are paid in cash.
and they are no longer a shareholder of the company.
That is what happen to many shareholders of ELCO Elcom International, Inc.

I bought 1 share back in 2021 just to keep track. It is -89%

PPBT...........................................https://stockcharts.com/h-sc/ui?s=PPBT&p=W&b=5&g=0&id=p86431144783

This thing is coming back to life…Finally

PPBT under $2